Daiichi Sankyo Co., Ltd. is a global pharmaceutical company headquartered in Tokyo, Japan. Established in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, the firm has grown into one of the leading Japanese research-driven healthcare organizations. It employs a vertically integrated business model, encompassing discovery research, clinical development, manufacturing and marketing of prescription medicines.
The company’s core focus areas include oncology, cardiovascular and metabolic diseases. Its oncology portfolio features trastuzumab deruxtecan (Enhertu), developed in collaboration with AstraZeneca, which has been approved for HER2-positive breast and gastric cancers. In cardiovascular care, Daiichi Sankyo markets products such as prasugrel (Effient) and olmesartan (Benicar) for the treatment and prevention of thrombotic and hypertensive disorders.
Daiichi Sankyo maintains a global footprint, with research and development centers in Japan, the United States and Europe. Its U.S. subsidiary, Daiichi Sankyo America, supports both clinical trials and commercial operations. The company also operates manufacturing facilities in Asia, North America and Europe, ensuring global supply of its key medicines and compliance with international regulatory standards.
Under the leadership of President and Chief Executive Officer Sunao Manabe, Daiichi Sankyo continues to invest in a robust pipeline, strategic alliances and next-generation technologies. The company’s long-term strategy emphasizes precision oncology, digital health initiatives and sustainable growth to address evolving patient needs and expand its presence in major pharmaceutical markets worldwide.
AI Generated. May Contain Errors.
